CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Open accessThe DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.
Abstract
CTL-associated antigen 4 (CTLA4) blockade releases inhibitory controls on T cell activation and proliferation, inducing antitumor immunity in both preclinical and early clinical trials. We examined the mechanisms of action of anti-CTLA4 and a GM-CSF-transduced tumor cell vaccine (Gvax) and their impact on the balance of effector T cells (Teffs) and Tregs in an in vivo model of B16/BL6 melanoma. Tumor challenge increased the frequency of Tregs in lymph nodes, and untreated tumors became infiltrated by CD4+Foxp3- and CD4+Foxp3+ T cells but few CD8+ T cells. Anti-CTLA4 did not deplete Tregs or permanently impair their function but acted in a cell-intrinsic manner on both Tregs and Teffs, allowing them to expand, most likely in response to self antigen. While Gvax primed the tumor-reactive Teff compartment, inducing activation, tumor infiltration, and a delay in tumor growth, the combination with CTLA4 blockade induced greater infiltration and a striking change in the intratumor balance of Tregs and Teffs that directly correlated with tumor rejection. The data suggest that Tregs control both CD4+ and CD8+ T cell activity within the tumor, highlight the importance of the intratumor ratio of effectors to regulators, and demonstrate inversion of the ratio and correlation with tumor rejection during Gvax/anti-CTLA4 immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti-CTLA-4 and anti-PD-1 antibodies have been successful in depleting tumor-infiltrating Tregs and increasing the effector T cell (Teff) to Treg ratio in the tumor microenvironment (Curran et al., 2010; Quezada et al., 2006; Simpson et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Quezada et al., 2006
Experimental — accuracy not yet measuredIn the citing paper
“Mouse melanoma models, for example, have shown that the combination of anti-CTLA-4 with cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or with agonistic antibodies targeting costimulatory receptors such as CD40, increased tumor rejection in a synergistic manner (121, 122).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [121]
In the citing paper
“In general, anti-CTLA4 expands CD4 effector T cells (Teff) with subsequent increase in the Teff/ Treg ratio in responding tumors (22).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Read, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Cited by
Items 501–600 of 697
Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?
Usón, P. L. S., Nagalo, B. M., Ahn, D. H., Bekaii‐Saab, T., & Borad, M. J. (2021) · Seminars in Liver Disease · doi:10.1055/s-0040-1722646 · Cited by 13
Explant Modeling of the Immune Environment of Head and Neck Cancer
Sharon, S., Duhen, T. M., Bambina, S., Baird, J. R., Leidner, R. S., Bell, B., Casap, N., Crittenden, M. R., Vasudevan, S., Jubran, M. R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.611365 · Cited by 14
Vaccination against Cancer or Infectious Agents during Checkpoint Inhibitor Therapy
Nasti, T. H., & Eberhardt, C. S. (2021) · Vaccines · doi:10.3390/vaccines9121396 · Cited by 12
Corradi, R. B., Rosa, S. P. L., Jebiwott, S., Murray, K. S., Rosenzweig, B., Somma, A. J., Gomez, R. S., Scherz, A. J., Kim, K., & Coleman, J. (2019) · International Journal of Urology · doi:10.1111/iju.13878 · Cited by 16
Ward, S., & Dalgleish, A. G. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.06.042 · Cited by 12
Joshi, K., Chain, B., Peggs, K. S., & Quezada, S. A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027086 · Cited by 14
“…that the antibodies can act both by blocking inhibitory signaling on effector T cells and by driving Fcg receptor-mediated depletion of tumor infiltrating regulatory T cells expressing higher levels of CTLA-4 than effector T cells (Quezada et al. 2006, 2008; Peggs et al. 2009; Simpson et al. 2013).”
BackgroundJackson, S. R., Berrien-Elliott, M. M., Meyer, J. M., Wherry, E. J., & Teague, R. M. (2013) · Immunological Investigations · doi:10.3109/08820139.2012.751397 · Cited by 16
“For example, CTLA-4 is upregulated on both exhausted and tolerant T cells, yet CTLA-4 blockade as a therapeutic modality has shown promise for tolerant (Curran et al., 2006; Quezada et al., 2006), but not exhausted T cells (Barber et al., 2006; Cecchinato et al., 2008).”
Mihalik, N. E., Wen, S., Driesschaert, B., & Eubank, T. D. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-021-02049-z · Cited by 11
Li, T., Liu, T., Zhao, Z., Pan, Y., Xu, X., Zhang, Y., Zhan, S., Zhou, S., Zhu, W., Guo, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.911325 · Cited by 13
“Depletion of regulatory T cells by anti-PD-1 or anti-CTLA-4 agents has been found to be able to effectively strengthen the effector T-cell function and thereby synergize ICB therapy efficacy (131, 132).”
BackgroundQian, F., & Han, B. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001124 · Cited by 13
“The response to anti-CTLA-4 treatment was related to the ratio of Teff to Tregs, and the higher the ratio, the better the response to treatment.([92,93]) A retrospective study reported that the high expression of FoxP3+ Tregs was associated with better prognosis in patients treated with anti-CTLA-4 therapy.”
BackgroundHuang, M., & Dong, J. (2021) · Journal of Immunology Research · doi:10.1155/2021/8816055 · Cited by 12
“Treg/Teff ratios have been suggested to correlate with effective antitumor responses [172].”
BackgroundTreatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015
Bok, R. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s905 · Cited by 11
“…are undoubtedly under consideration and may include use of such recombinant stimulatory cytokines as IL-12 (Saika et al 2004), IL-2, Interferon, or anti-CTLA4 (CTLA4 is an endogenous dampening factor for APC and antibodies have been developed which inhibit its effects; Quezada et al 2006).”
Khorsandi, S., Huntoon, K. M., Wang, Y., Woodward, A., Antony, A., Endsley, C., Hafeez, N., Edwards, J. L., Guenthner, N., Alluri, P. G., et al. (2025) · Advanced Science · doi:10.1002/advs.202416596 · Cited by 13
Vitale, M., Pagliaro, R., Viscardi, G., Pastore, L., Castaldo, G., Perrotta, F., Campbell, S. F. M., Bianco, A., & Scialò, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189244 · Cited by 12
“The ratio between Teff and Tregs is closely related to ICI responses, and the factors that stimulate Treg proliferation are presumptive biomarkers of resistance with a poor prognosis [68,69].”
Immunotherapy in Acute Leukemia
Leung, W. H. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.09.004 · Cited by 10
Wispelaere, W. D., Annibali, D., Tuyaerts, S., Lambrechts, D., & Amant, F. C. (2021) · Cancers · doi:10.3390/cancers13092040 · Cited by 11
“Furthermore, an increased ratio of Tregs to Teffs has been associated with poor response to ICB in pancreas cancer murine models, and the inability to decrease the ratio of Tregs to Teffs may result in resistance to immunotherapy [25,26].”
BackgroundCombined Tbet and IL12 Gene Therapy Elicits and Recruits Superior Antitumor Immunity In Vivo
Qu, Y., Chen, L., Lowe, D. B., Storkus, W. J., & Taylor, J. L. (2012) · Molecular Therapy · doi:10.1038/mt.2011.283 · Cited by 12
Exploring Synergy in Combinations of Tumor-Derived Vaccines That Harbor 4-1BBL, OX40L, and GM-CSF
Manrique-Rincón, A., Beraldo, C. M., Toscaro, J. M., & Bajgelman, M. C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01150 · Cited by 10
“Literature data also report utilization of one million irradiated cells or above, for in vivo experiments (41, 51).”
BackgroundSingh, S. K., Larsson, M., Schön, T., Stendahl, O. I., & Blomgran, R. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800523 · Cited by 10
Triggering immunogenic death of cancer cells by nanoparticles overcomes immunotherapy resistance
Mei, T., Ye, T., Huang, D., Xie, Y., Xue, Y., Zhou, D., Wang, W., & Chen, J. (2024) · Cellular Oncology · doi:10.1007/s13402-024-01009-6 · Cited by 12
Androulidaki, A., Liu, F., Bebber, C. M., Kisis, I., Sakthivelu, V., Hunold, P., Koerner, L., Dahlhaus, A., Yapici, F. I., Grimm, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67142-4 · Cited by 10
“Notably, transcriptional signatures of this cellular state are enriched in relapsed and metastatic human SCLC. Mechanistically, caspase 8 loss within the pre-tumoral niche promotes in fl ammation marked by increased recruitment of regulatory T cells (Tregs) which are responsible for the promotion of metastatic disease.”
InfluentialPreoperative immune checkpoint inhibition and cryoablation in early-stage breast cancer
Comen, E. A., Budhu, S., Elhanati, Y., Page, D. B., Ho, T. S., Ritter, E., Wong, P., Plitas, G., Patil, S., Brogi, E., et al. (2024) · iScience · doi:10.1016/j.isci.2024.108880 · Cited by 9
Urothelial cancers: using biology to improve outcomes
Pezaro, C., Liew, M. S., & Davis, I. D. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.195 · Cited by 10
“To be or not to Be”: Regulatory T cells in melanoma
Ibrahim, Y. S., Amin, A. H., Jawhar, Z. H., ALGhamdi, M. A., Al‐Awsi, G. R. L., Shbeer, A. M., AL-Ghamdi, H. S., Gabr, G. A., Ramírez‐Coronel, A. A., & Almulla, A. F. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110093 · Cited by 12
Translating 2A Research into Practice
Garry, A. (2012) · InTech eBooks · doi:10.5772/30091 · Cited by 10
Necroptotic‐susceptible dendritic cells exhibit enhanced antitumor activities in mice
Zhao, Z., Zhang, G., Sun, Y., & Winoto, A. (2020) · Immunity Inflammation and Disease · doi:10.1002/iid3.330 · Cited by 8
“However, we did observe a specific increase in the proportion of CD8 T cells in the TILs of both WT and FADD‐deficient DC‐treated groups over PBS controls (Figure 2D) as well as an increase in the CD8 to Treg ratio (Figure 2E), an indicator that has previously been associated with a strong antitumor response in reacti…”
BackgroundZhao, J., Ma, X., Li, Z., Deng, R., Wang, S.-M., Shen, G., Zhang, J., Wang, F., Zhang, B., & Wei, Y.-Q. (2014) · Clinical and Experimental Medicine · doi:10.1007/s10238-014-0277-6 · Cited by 12
“destruction [42–44].”
Fukushima, H., Furusawa, A., Takao, S., Thankarajan, E., Luciano, M., Usama, S. M., Kano, M., Okuyama, S., Yamamoto, H., Suzuki, M., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2370544 · Cited by 9
“The ratio of CD8 + T cells to Tregs, a well-known index of strong anti-cancer immunity, 27 was significantly increased in the tumor after CD25-targeted NIR-DPR (Figure 4d).”
BackgroundA comprehensive insights of cancer immunotherapy resistance
Das, L., & Das, S. (2025) · Medical Oncology · doi:10.1007/s12032-025-02605-8 · Cited by 12
“CD4 + and CD8 + T cells activity within the tumor mass, highlighting the importance of the intra-tumoral ratio between effectors and regulators, correlates with tumor rejection during GVAX / anti-CTLA-4 immunotherapy [85].”
Navarrete, M., Costoya, C., Gálvez‐Cancino, F., Peggs, K. S., Marabelle, A., & Quezada, S. A. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-123559 · Cited by 11
Mathematical Model for Delayed Responses in Immune Checkpoint Blockades
Zheng, C. Y., & Kim, P. (2021) · Bulletin of Mathematical Biology · doi:10.1007/s11538-021-00933-0 · Cited by 8
Tsaknakis, B., Schaefer, I., Schwörer, H., Sahlmann, C., Thoms, K., Blaschke, M., Ramadori, G. P., & Cameron, S. (2013) · Medical Oncology · doi:10.1007/s12032-013-0813-3 · Cited by 8
“It has been proposed that the CTLA4 blockade induces a greater infiltration of immune cells into the tumour and a change in the intra-tumour balance of regulatory T-cells to effector T-cells, which correlates with tumour rejection [28].”
BackgroundTao, R., Cheng, X., Wu, H., Wang, F., Ye, Z., & Wu, G. (2017) · Oncology Letters · doi:10.3892/ol.2017.7376 · Cited by 8
“It was hypothesized that PBMCs, when induced with a CIK cell cytokine cocktail, are activated and this trigged the activation of inhibitory signal to balance the immune response of CIK cells represented by the concurrent upregulation of CTLA-4 and CD28 (23,24).”
InfluentialZhang, L., Xu, L., Wang, Y., Liu, X., Zhang, M., & Li, W. (2020) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2020.01.022 · Cited by 8
Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer
Raza, A., Merhi, M., Relecom, A., Fernandes, Q., Inchakalody, V. P., Gul, A. R. Z., Shahab Uddin, M. S., Homsi, M. U. A., & Dermime, S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96494 · Cited by 10
Selecting antigens for cancer vaccines
Avogadri, F., & Wolchok, J. D. (2012) · Nature Biotechnology · doi:10.1038/nbt.2174 · Cited by 8
Myeloid-derived suppressor cells and the efficacy of CD8+T-cell immunotherapy
Lesokhin, A. M., Merghoub, T., & Wolchok, J. D. (2013) · OncoImmunology · doi:10.4161/onci.22764 · Cited by 8
“Results from preclinical studies suggest that favorable disease outcomes are associated with increases in effector to suppressor T-cell ratios at the tumor site.(1) In humans, an increased density of CD8 effector T cells, memory cells and T H 1 cytokines at the tumor site have been shown to correlate with a favorable…”
BackgroundAllison, J. P. (2015) · JAMA · doi:10.1001/jama.2015.11929 · Cited by 207
Promises and challenges of human papillomavirus vaccines for cervical cancer
Sin, J. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.9.1.1 · Cited by 8
Quesnel, B. (2006) · Expert Review of Vaccines · doi:10.1586/14760584.5.6.773 · Cited by 8
Ikeda, O., Kikuchi, A., Tsuzuki, H., Watanabe, H., Okuyama, K., Seki, Y., Ujihara, S., Matsuda, T., Weng, J., Kawashima, T., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0108 · Cited by 7
Singh, N. K., Madan, R. A., & Gulley, J. L. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.754421 · Cited by 8
“These observations are not definitive proof of the role of CTLA-4 in Treg suppressive function; in fact, contradictory evidence exists in both murine and human models [27-30].”
BackgroundEnhancing graft-versus-leukemia after transplant: the rise of anti-cancer vaccines
Brusic, A., & Wu, C. J. (2011) · Frontiers in bioscience · doi:10.2741/3949 · Cited by 7
“Histological analysis of tumor showed an increase in the CD8/T-reg ratio, as observed by other investigators (137).”
BackgroundCytotoxic T-lymphocyte Associated Antigen-4 (CTLA-4) Polymorphism, Cancer, and Autoimmune Diseases
Tanhapour, M., Vaisi‐Raygani, A., Khazaei, M., Rahimi, Z., & Pourmotabbed, T. (2017) · AIMS Medical Science · doi:10.3934/medsci.2017.4.395 · Cited by 9
Hirschhorn, D., Warner, A. B., Maniyar, R. R., Chow, A. T., Mangarin, L. M. B., Cohen, A. D., Hamadene, L., Rizzuto, G. A., Budhu, S., Suek, N., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151035 · Cited by 8
“It is known that an elevated ratio of CD8+ T cells/Tregs is predictive of immunotherapy efficacy (43).”
BackgroundFortis, S. P., Sofopoulos, M., Goulielmaki, M., Arnogiannaki, N., Ardavanis, A. S., Perez, S. A., Gritzapis, A. D., & Baxevanis, C. N. (2022) · Cancers · doi:10.3390/cancers14246208 · Cited by 9
“Decreased densities of Tregs intratumorally resulted in the failure of immunotherapies in preclinical tumor models and clinical studies [34,35].”
BackgroundAn old enzyme for current needs: adenosine deaminase and a dendritic cell vaccine for HIV
Martinez-Navío, J. M., Climent, N., Gallart, T., Lluís, C., & Franco, R. (2011) · Immunology and Cell Biology · doi:10.1038/icb.2011.81 · Cited by 10
Biology of Human Cutaneous Melanoma
Elias, E., Hasskamp, J. H., & Sharma, B. K. (2010) · Cancers · doi:10.3390/cancers2010165 · Cited by 8
Champiat, S., Garralda, E., Galvao, V., Cassier, P. A., Gomez‐Roca, C., Korakis, I., Grell, P., Naing, A., LoRusso, P. M., Mikyšková, R., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101967 · Cited by 9
“In the 10-week PD study, the animals were administered s.c. with nanril twice weekly at 40 m g/kg (starting on day 1) and PD was evaluated by flow cytometry of blood samples obtained on days (cid:1) 3, 5, 12, 19, 26, 33, 40, 47, 54, 61 and 66.”
Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody
van Elsas, M. J., van der Schoot, J. M. S., Bartels, A., Steuten, K., van Dalen, D., Wijfjes, Z., Figdor, C. G., van Hall, T., van der Burg, S. H., Verdoes, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158707 · Cited by 6
Isolation and Analysis of Tumor-Infiltrating Treg
Bergerhoff, K. F., & Pedersen, M. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2647-4_5 · Cited by 8
Update on vaccine development for renal cell cancer
Storkus, W. J. (2010) · Research and Reports in Urology · doi:10.2147/oaju.s7242 · Cited by 7
Scientifically based combination therapies with immuno‐oncology checkpoint inhibitors
Chew, H. Y., Dolcetti, R., & Simpson, F. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14338 · Cited by 6
“Studies showed that antiCTLA-4 led to an increase in intratumoural effector T cells/Tregs cell ratio, resulting in tumour rejection [50-53].”
BackgroundZhuo, M., Gorgun, F. M., Tyler, D. S., & Englander, E. W. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12943 · Cited by 6
“…with anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) and anti-PD-1 (programmed cell death protein-1) monoclonal antibodies has been successful in controlling many types of tumors (Quezada et al., 2006; Wei et al., 2019), it still benefits only a subset of patients (Wei et al., 2018).”
BackgroundGorgun, F. M., Widen, S. G., Tyler, D. S., & Englander, E. W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.701968 · Cited by 7
“7 melanoma mouse model (12), we have previously demonstrated that tumoral TLS polymerases are transiently elevated following intratumoral delivery of the DNA damaging chemotherapeutic drug, cisplatin (13) and that the antiCTLA-4/anti-PD-1 ICB regimen(14, 15), given inconjunctionwith intratumoral cisplatin, leads to co…”
BackgroundInfluentialNew capabilities of regulation of antitumor immune response
Григорьевна, К. З., Ивановна, Ч. А., Заботина, Т. Н., Витальевна, К. О., Slavina, E. G., & Анатольевна, Б. А. (2015) · Malignant tumours · doi:10.18027/2224-5057-2015-1-24-30 · Cited by 8
Somer, L. D., Fevery, S., Bullens, D. M. A., Rutgeerts, O., Lenaerts, C., Mathieu, C., Boon, L., Kasran, A., Waer, M., & Billiau, A. (2010) · Immunology Letters · doi:10.1016/j.imlet.2010.06.005 · Cited by 6
Immunotherapy and Cancer Therapeutics: Why Partner?
Emens, L. A., & Jaffee, E. M. (2007) · Elsevier eBooks · doi:10.1016/b978-012372551-6/50076-6 · Cited by 9
Nian, Z., Zhao, Q., He, Y., Xie, R., Liu, W., Chen, T., Huang, S., Dong, L., Huang, R. S., & Yang, L. (2023) · Clinical Oncology · doi:10.1016/j.clon.2023.09.011 · Cited by 5
Martínez-Vila, C., González‐Navarro, E. A., Teixidó, C., Martin, R., Aya, F., Juan, M., & Arance, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179506 · Cited by 5
Rowdo, F. P. M., Lacreu, M. L., & Mordoh, J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00103 · Cited by 5
“In murine models, CTLA-4 blockade leads to antitumor cytotoxicity, presenting an increased ratio of CD8:Treg in tumor infiltrates (Quezada et al., 2006).”
BackgroundCombined chemotherapy of platinum and fluorouracil promotes T cell–mediated antitumor immunity
Luo, Y., Pei, S., Xu, J., Xiao, Y., & Zhu, X. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa143 · Cited by 5
Non-small cell lung cancer in the era of immunotherapy
Huang, Q., Kemnade, J. O., Cornwell, L., Kheradmand, F., Sabichi, A. L., & Das, D. G. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.06.009 · Cited by 6
Gene Modified T Cell Therapies for Hematological Malignancies
Mock, U., Delhove, J. M. K. M., & Qasim, W. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.005 · Cited by 5
Peptide and Protein-Based Cancer Vaccines
Braun, M., Perret, R., Scholz, G., & Romero, P. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_5 · Cited by 6
Cavanagh, W., Tjoa, B. A., & Ragde, H. (2007) · Urology · doi:10.1016/j.urology.2007.06.1127 · Cited by 5
IGF2BP3 as a Novel Prognostic Biomarker and Therapeutic Target in Lung Adenocarcinoma
Hu, F., Hu, C., He, Y., Guo, L., Sun, Y., Han, C., Zhang, X., Ren, J., Han, J., Wang, J., et al. (2025) · Cells · doi:10.3390/cells14151222 · Cited by 7
“In tumor immunity, CD4+ Tem cells directly kill cancer cells, destroy tumor vasculature, and maintain leukocyte responses by secreting cytokines such as IFN γ and TNF [34,35].”
Li, H., Lei, Y., Tian, Y., Nie, H., Li, Y., & Mi, Y. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102437 · Cited by 12
“Preclinical models demonstrated complete tumor regression and sustained immunological memory in 40 – 60 % of anti-CTLA-4-treated mice, effects mechanistically linked to enhanced CD8 + effector T cell/Treg ratios (4.8 vs. 1.6 in controls) through FoxP3 + cell depletion [130].”
InfluentialImmune Co-signaling to Treat Cancer
Callahan, M. K., Wolchok, J. D., Allison, J. P., & Sharma, P. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_8 · Cited by 4
Targeting the tumor niche to treat cancer
Neelapu, S. S., & Sharma, P. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517389112 · Cited by 4
Manrique-Rincón, A., de Carvalho, A. C., de Camargo, M. E. R., Franchini, K. G., & Bajgelman, M. C. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.07.029 · Cited by 4
Aru, B., Soltani, M., Pehlivanoğlu, C., Gürlü, E., Ganjalıkhani-Hakemi, M., & Demirel, G. Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.789728 · Cited by 5
“An experimental study has reported that the Teffs/Tregs ratio can be used as a predictive marker, and with a higher ratio, a better response is expected (86).”
BackgroundMandal, U. K., & Kumar, M. (2022) · Drug Delivery Letters · doi:10.2174/2210303112666220422102459 · Cited by 4
Prieto, L. P., & Miguel, L. S. S. (2013) · Journal of Veterinary Internal Medicine · Cited by 4
Yuan, H., Peng, Y., Xiao, H., Mi, M., Munn, D. H., & He, Y. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103512 · Cited by 4
“The T effector/Treg ratio correlates with the outcome of tumor immunotherapy (58, 59).”
BackgroundDNA Vaccines against Infectious Diseases and Cancer
Han, D.-J., Weiner, D. B., & Sin, J. (2010) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2010.18.1.001 · Cited by 5
“Along with this, blocking or removal of Treg cells (known to inhibit T cell responses) has also been reported to increase vaccine-induced immune responses (van Elsas et al., 1999; Prasad et al., 2005; Comes et al., 2006; Quezada et al., 2006; Viehl et al., 2006), highlighting importance of deleting a negative immune f…”
BackgroundImmunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop
Houot, R., Gaulard, P., Schreiber, R. D., Mellman, I., Lambotte, O., Coulie, P. G., Fest, T., Korman, A. J., Levy, R., Shipp, M. A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1186323 · Cited by 4
(2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.5.567 · Cited by 4
“Antibody-mediated blockade of CTLA4, a CD28-related receptor known to downregulate T cell activation [3], may provide an additional approach for augmenting immune responses [60].”
BackgroundMicrobiota, probiotics and common skin cancer: Association and therapeutic application
Javaherian, M., Bakhtiari, R., Ajoudanifar, H., Shokri, S., & Mirzaie, A. (2022) · Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale · doi:10.4081/jbr.2022.10594 · Cited by 3
Naqash, A. R., Stroud, G., Collichio, F. A., Muzaffar, M., Sharma, N. J., & Walker, P. R. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1324212 · Cited by 3
“GMCSF that forms an integral component of T-VEC in generating its immunogenic potential, has been shown to moderate the adverse event profile as well as potentiate the antitumor response of ICB antibdies based on preclinical studies [17].”
BackgroundThe Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019
Ascierto, P. A., Bifulco, C. B., Galon, J., Garbe, C., Khleif, S. N., McQuade, J. L., Odunsi, K. O., Okada, H., Paulos, C. M., Quezada, S. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000921 · Cited by 4
Bouqdayr, M., Abbad, A., Baba, H., Saih, A., Wakrim, L., & Kettani, A. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2178509 · Cited by 3
“On one hand, the intrinsic effects on Treg cells are expressed by interactions of CTLA-4 with its ligand, thus dampening the activation or proliferation of Treg cells (Quezada et al., 2006).”
BackgroundCapturing and Tracking Clonal T-cell Response to Cancer Neoantigens
Shagina, I. A., Nakonechnaya, T. O., Izosimova, A. V., Shabalkina, A. V., Yuzhakova, D. V., Skatova, V. D., Lupyr, K. R., Muftakhutdinov, I., Izraelson, M., Davydov, A. N., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1216 · Cited by 4
Association of eczema with risk of pan-cancers: a two-sample Mendelian randomization study
Zhao, X., He, X., Liu, X., Geng, S., Wang, Y., Dang, Y., Zhang, R., Huang, X., Guo, W., & Ma, H. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000065 · Cited by 2
Engineered ipilimumab variants that bind human and mouse CTLA-4
Robison, B., Diong, S., Kumar, A., Moon, T. M., Chang, O. S.-S., Chau, B. H., Bee, C., Barman, I., Rajpal, A., Korman, A. J., et al. (2025) · mAbs · doi:10.1080/19420862.2025.2451296 · Cited by 3
“19 Consistent with the identification of 9D9 as a B7 ligand blocker, 20 the BC loop and the MYPPPY-motif FG loop are also the principal contact sites for B7 ligands (Figure 1e).”
YY1 expression and PD-1 regulation in CD8 T lymphocytes
Touboul, R., & Bonavida, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821909-6.00003-1 · Cited by 4
Immunology and Immunotherapy of Breast Cancer
Stagg, J., & Loi, S. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_23 · Cited by 2
Evasion of Cytotoxic Lymphocyte and Pulmonary Macrophage-Mediated Immune Responses in Lung Cancer
Hodge, S. J., & Hodge, G. L. (2015) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-17807-3_8 · Cited by 2
Demaria, S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00011-7 · Cited by 2
Emerging options for the treatment of melanoma – focus on ipilimumab
Roddie, C., & Peggs, K. S. (2014) · ImmunoTargets and Therapy · doi:10.2147/itt.s43522 · Cited by 2
“The intratumor ratio of cytotoxic T-cells to regulatory T-cells has been shown to correlate with tumor rejection in murine models following therapy, 67 though whether a baseline measurement prior to initiation of therapy in human cancers can predict outcome remains untested.”
Termini, J. M., Gupta, S., Raffa, F. N., Guirado, E., Fischl, M. A., Niu, L., Kanagavelu, S. K., & Stone, G. W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184915 · Cited by 2
Overcoming Cancer Tolerance with Immune Checkpoint Blockade
Clifton, G. T., Mittendorf, E. A., & Peoples, G. E. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_6 · Cited by 2
Artificial T Cell Mimetics to Combat Melanoma Tumor Growth
Mukundan, S., Guan, D., Singleton, A., Yang, Y., Li, M., & Parekkadan, B. (2018) · American Journal of Advanced Drug Delivery · doi:10.21767/2321-547x.1000023 · Cited by 2
Where do the Immune Checkpoint Inhibitors Stand in the Management of Triple Negative Breast Cancer?
Rassy, E., Karak, F. E., & Ghosn, M. G. (2018) · Immunotherapy · doi:10.2217/imt-2017-0171 · Cited by 2
Gracia, G., Cao, E., Yuen, D., Ferreira, V. D. M., Chen, M. Z., Senyschyn, D., Mintern, J. D., Johnston, A. P. R., Kang, D. W., Feeney, O. M., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0256 · Cited by 2
Targeting Immunological Synapse: New Horizons in Immunotherapy for Cancer
Chmielowski, B., & Ribas, A. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-087-8_48 · Cited by 1
Poxvirus-Based Strategies for Combined Vaccine and Tumor Microenvironment Manipulation
de Vries, C. R., Poplin, E. A., Weiss, R. E., August, D. A., Gabriel, E. M., DiPaola, R. S., & Lattime, E. C. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394295-1.00017-2 · Cited by 1
Releasing the Brakes in Cancer
Dubey, S., & Garg, A. (2016) · Journal of Bioanalysis & Biomedicine · doi:10.4172/1948-593x.1000147
“In poorly immunogenic tumors, combination of CTLA-4 blockade with GM-CSF based tumor vaccine showed better results as compared to CTLA-4 monotherapy alone [20].”
ResultIntroduction on Immune Checkpoints in Cancer
Balibegloo, M., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_158-1 · Cited by 1
Immunotherapy for Prostate Cancer—Why Now?
Kates, M. R., & Drake, C. G. (2016) · Urology Practice · doi:10.1016/j.urpr.2016.07.010 · Cited by 1
Metadata
- Authors
- Quezada, S. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Quezada, S. A.
- ORCID
- Quezada, S. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1935-1945
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1479425
- OpenAlex
- W2131874142
- Cited by
- 700
- References
- 50
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 22 · 2023: 37 · 2022: 31 · 2021: 44 · 2020: 35 · 2019: 37 · 2018: 41 · 2017: 46 · 2016: 29 · 2015: 41 · 2014: 41 · 2013: 39 · 2012: 38
- FWCI
- 18.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, GM-CSF, GVAX, tumor cell vaccine, regulatory T cells, effector T cells, B16-BL6 melanoma, antitumor immunity, Foxp3, CD8+ T cells, CD4+ T cells, tumor rejection, combination immunotherapy
- MeSH terms
- Animals, Antigens, Differentiation, Immunotherapy, Lymph Nodes, Melanoma, Experimental, Mice, Inbred C57BL, Antigens, CD, CD4 Antigens, T-Lymphocyte Subsets, Granulocyte-Macrophage Colony-Stimulating Factor, CD8 Antigens, Cancer Vaccines, Cell Line, Tumor, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.